CD8A and neoplasm: By contrast, Batf3-DCs are indispensable for cross-priming of CD8+ T cells and generating de novo anti-tumor T cell responses, therefore, expanding intratumoral DCs is a rational alternative approach to augment oncolytic virotherapy.